test pipeline

Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
COVID-19 Programs

COVI-TRACE™ (diagnostic) Diagnostic Test

0%*

FDA Emergency Use Authorization (EUA) Application Expected

COVI-STIX™ (diagnostic) Antigen Test

0%*

FDA Emergency Use Authorization (EUA) Application Expected

COVI-TRACK™ (diagnostic) Antibody Test

0%*

FDA Emergency Use Authorization (EUA) Application Under Review

COVI-GUARD™ (treatment) Neutralizing Antibody (IV) in Inpatients

30%*

COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients

30%*

COVI-DROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients

10%*

COVI-SHIELD™ (treatment) Neutralizing Abs (IV) in Inpatients

10%*

COVIDTRAP™ (treatment) ACE2 Receptor Decoy (IV) in Inpatients

10%*

ABIVERTINIB (treatment) Severe or Critical COVID-19 in ICU Patients

55%*

SALICYN – 30 (treatment) Anti-viral

10%*

COVI-MSC (treatment) ARDS due to COVID-19 in ICU Pts

30%*

Immunotherapy

CD38 CAR-T Multiple Myeloma

30%*

CD38 DAR-T Multiple Myeloma

10%*

CD38 ADC Amyloidosis

30%*

Seprehvir™ Solid Tumors

30%*

Seprehvec™ Solid Tumors

30%*

ABIVERTINIB NSCLC

80%*

ADNIC Solid and Liquid Tumors

55%*

Pain

RTX (resiniferatoxin)
Epidural route
Intractable Pain in Advanced Cancer

55%*

Orphan designation

RTX (resiniferatoxin)
Intra-articular route
Moderate to Severe OA

55%*

Lymphatic Delivery

Sofusa® anti-TNF Autoimmune

30%*

Sofusa® anti-PD-1 CTCL

30%*

COVID-19 Programs
Key Programs (Indication) Phase
COVI-TRACE™ (diagnostic) FDA EUA
COVI-STIX™ (diagnostic) FDA EUA
COVI-TRACK™ (diagnostic) FDA EUA
COVI-GUARD™ (treatment) Ph I
COVI-AMG™ (treatment) Ph I
COVI-DROPS™ (treatment) Preclinical
COVI-SHIELD™ (treatment) Preclinical
COVIDTRAP™ (treatment) Preclinical
ABIVERTINIB (treatment) Ph II
SALICYN – 30 (treatment) Preclinical
COVI-MSC (treatment) Ph I
Immunotherapy
Key Programs (Indication) Phase
CD38 CAR-T (Multiple Myeloma) Ph I
CD38 DAR-T (Multiple Myeloma) Preclinical
CD38 ADC (Amyloidosis) Ph I
Seprehvir™ (Solid Tumors) Ph I
Seprehvec™ (Solid Tumors) Ph I
ABIVERTINIB (NSCLC) PhIII/Pivotal
ADNIC (Solid and Liquid Tumors) Ph II
Pain
Key Programs (Indication) Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II
RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II
Lymphatic Delivery
Key Programs (Indication) Phase
Sofusa® anti-TNF (Autoimmune) Ph I
Sofusa® anti-PD-1 (Immuno Oncology) Ph I
Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
COVID-19 Programs  

COVISTIX™ (diagnostic) Rapid Antigen Test

*

Emergency Use Authorization (EUA) in Mexico (COFEPRIS), Brazil (ANVISA), and CE Marked in Europe

COVIMARK™ (diagnostic) Rapid Antigen Test

*

Application submitted in the US and Canada for Emergency Use Authorization (EUA)

COVISHIELD™ (treatment) Neutralizing Antibody (IN) in Outpatients and Inpatients

40%*

COVISHIELD™ (treatment) Neutralizing Antibody (IV) in Outpatients and Inpatients

20%*

FUJOVEE™ (Abivertinib) Severe COVID-19 in ICU Patients

82%*

Pivotal Trial Pending FDA Clearance

OQORY™ (COVI-MSC) ARDS due to COVID-19 in ICU Patients

82%*

Pivotal Trial in Brazil

Mpro Inhibitor (oral pill) Anti-viral

20%*

Omicron mRNA Vaccine Vaccine

20%*

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*In Partnership with Lee’s Pharm in China

PD-L1 (STI-3031)** Cervical Cancer

82%*

**In US and in partnership with ImmuneOncia in Korea

CD47 Solid Tumors

40%*

CD38 DAR-T Multiple Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, and esophageal

40%*

TROP2 ADC* Solid Tumors

40%*

* In China

Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors

40%*

BCMA ADC Liquid Tumors

20%*

Bevacizumab-ADNAB™ Endometrial Cancer

40%*

In partnership with Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Cancer

40%*

In partnership with Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

In partnership with Mayo Clinic
Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Pain  

ZTlido™ 1.8%
Postherpetic Neuralgia - PHN

99.8%*

SP-102 (SEMDEXA) Lumbar Radicular/Sciatica Pain

82%*

SP-103 (Lidocaine Topical System 5.4%) Acute Back Pain

20%*

SP-104 (Delayed Burst Low Dose Naltrexone) Fibromyalgia

20%*

RTX (resiniferatoxin)
Epidural injection
Intractable Pain in Advanced Cancer

60.3%*

Orphan designation

RTX (resiniferatoxin)
Intra-articular route
Moderate to Severe Knee OA Pain

60.2%*

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Lymphatic Delivery  

Sofusa® anti-TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

In partnership with Mayo Clinic
COVID-19 Programs
Key Programs (Indication) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
COVISHIELD™ (treatment) PH I
COVISHIELD™ (treatment) Preclinical
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (oral pill) (anti-viral) Preclinical
Omicron mRNA Vaccine (vaccine) Preclinical
Immunotherapy
Key Programs (Indication) Phase
FUJOVEE™ (Abivertinib) (NSCLC) Ph III
FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II
FUJOVEE™ (Abivertinib) (Prostate) Preclinical
FUJOVEE™ (Abivertinib) (Lupus) Preclinical
FUJOVEE™ (Abivertinib) (MS) Preclinical
FUJOVEE™ (Abivertinib) (GvHD) Preclinical
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Cervical Cancer) Ph III
CD47 (Solid Tumors) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I
TROP2 ADC* (Solid Tumors) Ph I
Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I
BCMA ADC (Liquid Tumors) Preclinical
Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Pain
Key Programs (Indication) Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
SP-102 (SEMDEXA) Ph III
SP-103 (Lidocaine Topical System 5.4%) Preclinical
SP-104 (Delayed Burst Low Dose Naltrexone) Preclinical
RTX (resiniferatoxin) Epidural injection (Intractable Pain in Advanced Cancer) Ph II
RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA Knee Pain) Ph II
Lymphatic Delivery
Key Programs (Indication) Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I